Comparison of the Bulb Aspirator to a Nasal Oral Aspirator in the Treatment of Bronchiolitis

April 18, 2019 updated by: Whitney Schwarz, University of Texas at Austin
The investigators aim to compare the standard bulb aspirator with that of a nasal oral aspirator. The hypothesis is that use of a nasal oral aspirator is more effective at removing nasal secretions in the treatment of bronchiolitis as measured by a predicted 50% decrease in the rate of unscheduled bronchiolitis return visits. The primary endpoint will be the number of unscheduled bronchiolitis return visits; secondary endpoints will include measurements of oral intake, respiratory relief, parental device preference and adverse events.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

This study will be a single center, single blind, randomized controlled trial in the pediatric emergency department (ED) at Dell Children's Medical Center of Central Texas (DCMC). An ED discharge diagnosis of bronchiolitis will trigger patients to be randomized to receive a bulb aspirator or nasal oral aspirator for home secretion management use. Prior to dispensing the randomized aspirator, a pre-distribution questionnaire will be administered. Additionally, patients will receive a diary to complete for 3 days post ED discharge. Research personnel will call families on day 4 as a reminder to return the diary and again on day 14 to obtain a verbal post-study questionnaire. Research personnel will perform chart review on all patients looking for unscheduled patient return visits for bronchiolitis.

Study Type

Interventional

Enrollment (Actual)

236

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Texas
      • Austin, Texas, United States, 78723
        • Dell Children's Medical Center of Central Texas

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 month to 2 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Children >28 days of life to < 2 years of age discharged home from the DCMC ED with a diagnosis of bronchiolitis (diagnosis made per provider discretion)
  • Caregiver fluent in English or Spanish

Exclusion Criteria:

  • Previous enrollment
  • Hospital admission
  • Parental refusal to be randomized to an aspirator device (i.e., family prefers current device and does not wish to be randomized to a potentially different product)
  • Current bacterial pneumonia
  • Diagnosis of asthma
  • Chronic lung disease
  • Significant underlying cardiac disease
  • Chronic neuromuscular disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Bulb Aspirator
If randomized to the bulb aspirator group, the patient will be sent home with a bulb aspirator to use for home nasal secretion management
Experimental: Nasal Oral Aspirator (NeilMed Naspira)
If randomized to the nasal oral aspirator group, patient will be sent home with a nasal oral aspirator to use for home nasal secretion management
NeilMed Naspira is a nasal-oral aspirator

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Unscheduled bronchiolitis return visits
Time Frame: 14 days
The number of unscheduled bronchiolitis return visits (return to either ED, urgent care or PCP)
14 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Oral intake
Time Frame: 14 days
Effects of device on oral intake as determined by diary and post-study questionnaire
14 days
Respiratory relief
Time Frame: 14 days
Effects of device on respiratory relief as determined by diary and post-study questionnaire
14 days
Parental device preference
Time Frame: 14 days
Parental device preference as determined by diary and post-study questionnaire
14 days
Adverse events
Time Frame: 14 days
Description of adverse events as determined by diary and post-study questionnaire
14 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 22, 2017

Primary Completion (Actual)

March 21, 2019

Study Completion (Actual)

March 21, 2019

Study Registration Dates

First Submitted

September 13, 2017

First Submitted That Met QC Criteria

September 15, 2017

First Posted (Actual)

September 20, 2017

Study Record Updates

Last Update Posted (Actual)

April 19, 2019

Last Update Submitted That Met QC Criteria

April 18, 2019

Last Verified

April 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bronchiolitis

Clinical Trials on NeilMed Naspira

Subscribe